Posted on

Ridgepost Capital Completes Acquisition of Stellus Capital Management, a Leading U.S. Direct Lender Specializing in the Lower-Middle Market

DALLAS, June 22, 2026 (GLOBE NEWSWIRE) — Ridgepost Capital, Inc. (NYSE: RPC) (“Ridgepost” or “Ridgepost Capital”) today announced it has completed its previously announced acquisition of Stellus Capital Management, LLC (“Stellus”), a leading U.S. direct lender focused on the lower-middle market with approximately $4 billion in assets under management. Stellus will continue to be managed by its current partners who will lead day-to-day operations, including investment decisions and investment committee processes.

By sf-admin
Posted on

Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right (“CVR”) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones, for a total transaction value of approximately $7.8 billion (the “Transaction”).

By sf-admin
Posted on

MIT Found 95% of Corporate AI Projects Show NO Measurable Financial Return. Former White House and Pentagon Advisor Asks What That Means for Investors

A widely cited MIT study found almost no measurable corporate profits from generative AI so far. A former Pentagon and CIA advisor puts that finding next to the valuations investors are paying. 

A widely cited MIT study found almost no measurable corporate profits from generative AI so far. A former Pentagon and CIA advisor puts that finding next to the valuations investors are paying.

By sf-admin
Posted on

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologics, along with ongoing clinical research, is expanding the treatment landscape for CLE patients. 

The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologics, along with ongoing clinical research, is expanding the treatment landscape for CLE patients.

By sf-admin
Posted on

Callan Family Office Named to Inaugural CNBC Elite Advisors List, Recognizing the Nation’s Leading Ultra-High-Net-Worth Advisory Firms

PHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) — Callan Family Office, a registered investment advisor serving ultra-high-net-worth families, family offices, foundations, and endowments, today announced it has been named to the first-ever CNBC Elite Advisors list. The inaugural recognition identifies 25 independent advisory firms across the United States that specialize in serving ultra-high-net-worth individuals, families, and family offices with investable assets of $25 million or more.

By sf-admin
Posted on

Laboratory Developed Tests Market Size to Reach USD 28.31 Billion by 2035 | SNS Insider

The U.S. Laboratory Developed Tests Market is projected to grow from USD 5.97 Billion in 2025 to USD 11.85 Billion by 2035, while Europe is expected to expand from USD 3.75 Billion to USD 7.55 Billion, supported by growing precision oncology adoption, expanding genomic medicine initiatives, and increasing demand for advanced molecular diagnostics. 

The U.S. Laboratory Developed Tests Market is projected to grow from USD 5.97 Billion in 2025 to USD 11.85 Billion by 2035, while Europe is expected to expand from USD 3.75 Billion to USD 7.55 Billion, supported by growing precision oncology adoption, expanding genomic medicine initiatives, and increasing demand for advanced molecular diagnostics.

By sf-admin